BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 24685356)

  • 1. Stage III non-small-cell lung cancer: Establishing a benchmark for the proportion of patients suitable for radical treatment.
    Al-Shamsi HO; Al Farsi A; Ellis PM
    Clin Lung Cancer; 2014 Jul; 15(4):274-80. PubMed ID: 24685356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wait times in diagnostic evaluation and treatment for patients with stage III non-small cell lung cancer in British Columbia.
    Wai ES; Mackinnon M; Hooker R; Moccia P; Perry KR; Truong PT
    Am J Clin Oncol; 2012 Aug; 35(4):373-7. PubMed ID: 21422900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age ≥ 70 years).
    Aridgides PD; Janik A; Bogart JA; Duffy S; Rosenbaum P; Gajra A
    Clin Lung Cancer; 2013 Nov; 14(6):674-9. PubMed ID: 23891240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
    Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
    J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
    Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
    Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age and treatment of non-small-cell lung cancer: a database analysis in elderly patients.
    Berghmans T; Tragas G; Sculier JP
    Support Care Cancer; 2002 Nov; 10(8):619-23. PubMed ID: 12436220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of weight change during the course of concurrent chemoradiation therapy on outcomes in stage IIIB non-small cell lung cancer patients: retrospective analysis of 425 patients.
    Topkan E; Parlak C; Selek U
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):697-704. PubMed ID: 24035331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
    Wakelee HA; Bernardo P; Johnson DH; Schiller JH
    Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
    Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function.
    Dickhoff C; Hartemink KJ; van de Ven PM; van Reij EJ; Senan S; Paul MA; Smit EF; Dahele M
    Lung Cancer; 2014 Aug; 85(2):218-23. PubMed ID: 24976333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.
    Russell K; Healy B; Pantarotto J; Laurie SA; MacRae R; Sabri E; Wheatley-Price P
    Clin Lung Cancer; 2014 May; 15(3):237-43. PubMed ID: 24461300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
    Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
    J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.
    Gielda BT; Mehta P; Khan A; Marsh JC; Zusag TW; Warren WH; Fidler MJ; Abrams RA; Bonomi P; Liptay M; Faber LP
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):985-91. PubMed ID: 20932684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.
    Brule SY; Al-Baimani K; Jonker H; Zhang T; Nicholas G; Goss G; Laurie SA; Wheatley-Price P
    Lung Cancer; 2016 Jul; 97():15-21. PubMed ID: 27237022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status.
    Maguire J; Khan I; McMenemin R; O'Rourke N; McNee S; Kelly V; Peedell C; Snee M
    Eur J Cancer; 2014 Nov; 50(17):2939-49. PubMed ID: 25304298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer.
    Arslan D; Tural D; Koca T; Tastekin D; Kaymak Cerkesli A; Basaran H; Gunduz S; Murat Tatli A; Sezgin Goksu S; Uysal M; Kargi A; Kargi B; Koral L; Ibrahim Bassorgun C; Unal D; Mutlu H; Senol Coskun H; Ozdogan M; Bozcuk H
    J BUON; 2015; 20(2):573-9. PubMed ID: 26011352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
    Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
    Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in stage III non-small-cell lung cancer.
    Ademuyiwa FO; Johnson CS; White AS; Breen TE; Harvey J; Neubauer M; Hanna NH
    Clin Lung Cancer; 2007 Sep; 8(8):478-82. PubMed ID: 17922971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.